Physician profile
David Deuser
NPI 1427237015
$14,380.53
in general payments reported to CMS, 2019-2025
33 companies · $3,339 in 2025
The $3,339 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $505 · 2021: $1,668 · 2022: $2,018 · 2023: $3,170 · 2024: $2,830 · 2025: $3,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,227 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,227.36 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,578.23 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,259.12 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,240.84 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,229.74 | 2019-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $886.68 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $877.54 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $702.22 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $689.93 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $616.74 | 2020-2025 | Trintellix |
| Tris Pharma INC | $547.68 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Almatica Pharma LLC | $492.45 | 2021-2025 | Loreev Xr, Gralise |
| Corium, LLC | $440.04 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $388.45 | 2019-2025 | Fanapt |
| Neuronetics, INC. | $380.48 | 2025 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $324.89 | 2019-2023 | Jornay Pm |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $313.25 | 2020-2025 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $275.58 | 2024-2025 | Cobenfy |
| Indivior INC. | $273.84 | 2021-2025 | Sublocade |
| Neos Therapeutics, LP | $272.02 | 2021-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $259.26 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $258.64 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.28 | 2021-2025 | Caplyta |
| Allergan, INC. | $173.69 | 2019-2020 | |
| Braeburn INC. | $173.25 | 2023-2025 | Brixadi |
| Avanir Pharmaceuticals, INC. | $164.47 | 2019-2022 | |
| Eisai INC. | $79.54 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $58.30 | 2023-2024 | Quviviq |
| Brainsway USA INC | $50.64 | 2019-2020 | |
| Shire North American Group INC | $48.64 | 2019 | |
| Noven Therapeutics, LLC | $44.01 | 2024 | Xelstrym, Secuado |
| Acadia Pharmaceuticals INC | $40.97 | 2023-2024 | Nuplazid |
| Collegium Pharmaceutical, INC. | $24.16 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $16.96 | 2023 | Lamotrigine, Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Deuser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.